PRX 303
Alternative Names: PRX-303Latest Information Update: 28 Nov 2022
At a glance
- Originator PRAZER THERAPEUTICS
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Alpha-synuclein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Parkinson's disease
Most Recent Events
- 25 Nov 2022 Early research in Parkinson's disease in South Korea (unspecified route) (Prazer Therapeutics pipeline, November 2022)